Sponsors
The bill narrows orphan-drug exclusivity to specific approved uses to speed some approvals and increase near-term competition and regulatory clarity, but it risks weakening long-term incentives for rare-disease R&D and creates retroactive legal/commercial uncertainty for existing sponsors.
Hospitals, health systems, and drug developers gain clearer rules because the bill defines 'approved use or indication' more precisely, reducing regulatory uncertainty for FDA reviews and sponsors.
Patients with rare diseases could see faster availability of alternative treatments for different indications because exclusivity would block only the same approved use/indication, allowing timely non-infringing approvals.
Medicaid beneficiaries and some patients may benefit from increased competition for non-identical indications, which could lower prices or expand treatment options over time.
Patients with rare conditions and potential future markets could face fewer new drugs because narrowing exclusivity weakens incentives for sponsors to invest in developing treatments.
Patients with rare diseases risk reduced long‑term access to innovative therapies if developers reduce R&D investment in certain orphan indications due to narrower protection.
Existing orphan drug sponsors, licensors, and financial stakeholders could face legal or commercial uncertainty because the change would apply retroactively to all designated drugs.
Based on analysis of 2 sections of legislative text.
Introduced January 28, 2026 by Tammy Baldwin · Last progress January 28, 2026
Changes how orphan-drug exclusivity is compared: instead of blocking approvals for drugs that treat the “same disease or condition,” exclusivity would block only drugs with the same FDA-approved use or indication. The bill adds a definition of “approved use or indication” tied to approvals under the Food, Drug, and Cosmetic Act and licensure under the Public Health Service Act, and the change applies to any orphan-designated drug regardless of past designation or approval dates. The effect is to narrow the scope of seven-year orphan exclusivity so that competing products for different approved uses within the same disease may be eligible for approval, while products seeking the identical approved indication remain blocked during exclusivity.